Matinas BioPharma (MTNB) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
August 10, 2021 6:31 AM EDTEnrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021
Positive recent FDA feedback on MAT2501 (oral amikacin) development program allows for initiation of Phase 1 study in healthy volunteers in Q4 2021
In vitro studies of lipid nanocrystal (LNC) formulations of Gilead Sciences remdesivir demonstrate meaningful efficacy compared to free remdesivir, with a favorable toxicity profile; National Institute of Allergy and Infectious Diseases (NIAID) preparing to initiate an in vivo... More
